Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata
January 3, 2019 — Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 2b/3 clinical trial for its
Read more